Avapritinib versus Placebo in Indolent Systemic Mastocytosis
Jason Gotlib,Mariana Castells,Hanneke Oude Elberink,Frank Siebenhaar,Karin Hartmann,Sigurd Broesby-Olsen,Tracy I George,Jens Panse,Iván Alvarez-Twose,Deepti H Radia,Tsewang Tashi,Cristina Bulai Livideanu,Vito Sabato,Mark Heaney,Paul Van Daele,Sonia Cerquozzi,Ingunn Dybedal,Andreas Reiter,Thanai Pongdee,Stéphane Barete,Celalettin Ustun,Lawrence Schwartz,Brant R Ward,Philippe Schafhausen,Peter Vadas,Prithviraj Bose,Daniel J DeAngelo,Lindsay Rein,Pankit Vachhani,Massimo Triggiani,Patrizia Bonadonna,Mark Rafferty,Nauman M Butt,Stephen T Oh,Friederike Wortmann,Johanna Ungerstedt,Mar Guilarte,Minakshi Taparia,Andrew T Kuykendall,Cecilia Arana Yi,Princess Ogbogu,Caroline Gaudy-Marqueste,Mattias Mattsson,William Shomali,Matthew P Giannetti,Ilda Bidollari,Hui-Min Lin,Erin Sulllivan,Brenton Mar,Robyn Scherber,Maria Roche,Cem Akin,Marcus Maurer
DOI: https://doi.org/10.1056/EVIDoa2200339
Abstract:BACKGROUND: Indolent systemic mastocytosis (ISM) is a clonal mast-cell disease driven by the KIT D816V mutation. We assessed the efficacy and safety of avapritinib versus placebo, both with best supportive care, in patients with ISM. METHODS: We randomized patients with moderate to severe ISM (total symptom score [TSS] of ≥28; scores range from 0 to 110, with higher numbers indicating more severe symptoms) two to one to avapritinib 25 mg once daily (n=141) or placebo (n=71). The primary end point was mean change in TSS based on the 14-day average of patient-reported severity of 11 symptoms. Secondary end points included reductions in serum tryptase and blood KIT D816V variant allele fraction (≥50%), reductions in TSS (≥50% and ≥30%), reduction in bone marrow mast cells (≥50%), and quality of life measures. RESULTS: From baseline to week 24, avapritinib-treated patients had a decrease of 15.6 points (95% CI, −18.6 to −12.6) in TSS compared to a decrease of 9.2 points (−13.1 to −5.2) in the placebo group; P<0.003. From baseline to Week 24, 76/141 patients (54%; 45% to 62%) in the avapritinib group compared to 0/71 patients in the placebo group achieved a ≥50% reduction in serum tryptase level; P<0.001. Edema and increases in alkaline phosphatase were more common with avapritinib than placebo; there were few treatment discontinuations because of adverse events. CONCLUSIONS: In this trial, avapritinib was superior to placebo in reducing uncontrolled symptoms and mast-cell burden in patients with ISM. The long-term safety and efficacy of this approach for patients with ISM remain the focus of the ongoing trial. (Funded by Blueprint Medicines Corporation; ClinicalTrials.gov number, NCT03731260.)